Product image of Meriofert Spuit (Luteinising Hormone (Human), Follicle-Stimulating Hormone) supplied by GNH India

Meriofert Spuit

Active Ingredient:
Luteinising Hormone (Human), Follicle-Stimulating Hormone
Origin:
EU

Meriofert Spuit (Luteinising Hormone (Human), Follicle-Stimulating Hormone)

Human Menopausal Gonadotropin, the active ingredient in Meriofert Spuit, is a gonadotropin presented as an injectable solution for intramuscular or subcutaneous use. It stimulates ovarian follicular development and ovulation in women with anovulation or hypogonadotropic hypogonadism.
GNH India supplies Meriofert Spuit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Ibsa Farmaceutici Italia

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Meriofert Spuit is a gonadotropin used in reproductive‑hormone pathways to promote follicular growth and ovulation.

  • Induction of ovulation in women with anovulation: restores natural ovulatory cycles to enable conception.
  • Controlled ovarian stimulation for assisted reproductive technologies: enhances follicle recruitment for IVF or ICSI procedures.
  • Treatment of hypogonadotropic hypogonadism: replaces deficient LH and FSH to support normal ovarian function.

How It Works

  • Human Menopausal Gonadotropin contains both LH and FSH molecules that bind to their respective receptors on ovarian granulosa and theca cells. Activation of these receptors triggers intracellular signaling cascades that promote follicular maturation, estrogen synthesis, and the final ovulatory surge, thereby facilitating oocyte release and supporting early luteal phase function.

Side Effects

Adverse reactions may occur with any injectable reproductive hormone therapy.

Common Side Effects

  • Injection site pain or erythema: mild discomfort at the administration site.
  • Abdominal bloating or discomfort: transient gastrointestinal symptoms.
  • Headache: mild to moderate intensity.
  • Nausea: occasional upset stomach.
  • Mild ovarian cyst formation: small, self‑limiting cysts.

Serious or Rare Side Effects

  • Ovarian hyperstimulation syndrome (OHSS): severe fluid shift and abdominal distension.
  • Multiple pregnancy: higher-order gestations requiring specialized care.
  • Thromboembolic events: rare clot formation in veins.
  • Severe allergic reaction: anaphylaxis with rash, swelling, or breathing difficulty.
  • Ovarian torsion: acute pelvic pain due to twisted ovary.

Precautions & Warnings

Use Meriofert Spuit only under specialist supervision with appropriate monitoring.

  • Baseline assessment: evaluate ovarian reserve and hormonal profile before initiating therapy.
  • Monitor estradiol: frequent serum estradiol measurements to detect excessive response.
  • Avoid in pregnancy: contraindicated in confirmed pregnancy; ensure effective contraception.
  • Caution with ovarian cysts: assess for existing cysts prior to treatment.
  • Screen for hormone‑sensitive tumors: avoid use in patients with active estrogen‑dependent cancers.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Drug interactions may modify the efficacy or safety of Meriofert Spuit.

Major Interactions (Avoid)

  • Concurrent use of other gonadotropins: may cause excessive ovarian stimulation.
  • High‑dose estrogen therapy: can blunt the intended ovarian response.

Moderate Interactions (Monitor Closely)

  • GnRH agonists or antagonists: may require dose adjustment of hMG.
  • Anticoagulants: monitor for increased bleeding risk at injection sites.
  • Corticosteroids: may alter hormonal metabolism and require observation.

Frequently Asked Questions

Meriofert Spuit is an injectable preparation of human menopausal gonadotropin (LH and FSH) used to induce ovulation in women with anovulation, to stimulate the ovaries during assisted reproductive technologies such as IVF, and to treat hypogonadotropic hypogonadism by replacing deficient gonadotropins.

The preparation contains both luteinising hormone (LH) and follicle‑stimulating hormone (FSH). These hormones bind to LH and FSH receptors on ovarian cells, activating signaling pathways that promote follicle growth, estrogen production, and the final ovulatory surge, thereby enabling oocyte release and supporting early luteal function.

The dose of Meriofert Spuit is individualized. A qualified prescriber determines the amount, frequency, and duration based on the patient’s ovarian reserve, response to treatment, and the specific assisted‑reproduction protocol being used.

Meriofert Spuit is contraindicated in confirmed pregnancy and should not be used by women who are breastfeeding. It is intended for use before conception to induce ovulation; safety data in pregnancy and lactation are not established.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Compared with recombinant FSH or LH products, Meriofert Spuit provides a combined LH/FSH formulation derived from human urine, offering a broader hormonal profile. It may be preferred in protocols requiring both hormones, while recombinant preparations deliver highly purified single‑component dosing. Choice depends on clinical protocol, cost considerations, and patient response.

Meriofert Spuit must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Keep the vials in their original packaging until use and discard any product that appears discolored or contains particles.

The product is supplied as a sterile injectable solution for intramuscular or subcutaneous injection. Administration is performed by a qualified healthcare professional using aseptic technique, typically in the gluteal muscle or abdominal subcutaneous tissue, according to the prescriber’s dosing schedule.

The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can cause severe abdominal pain, fluid accumulation, and thromboembolic complications, as well as the possibility of multiple pregnancy and rare severe allergic reactions such as anaphylaxis. Patients should be monitored closely for these events.

Meriofert Spuit should not be used in women who are already pregnant, have uncontrolled thyroid disease, active estrogen‑dependent tumors, untreated ovarian cysts, severe ovarian failure, or known hypersensitivity to any component of the formulation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Luteinising Hormone (Human), Follicle-Stimulating Hormone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT